Discover how data-driven solutions have helped stakeholders in Precision Medicine drive growth and stay ahead of the curve. From RNA-based oncology biomarker market landscapes to NIPT market strategy and hereditary cancer testing opportunity assessments, deep expertise in precision diagnostics is applied across the full commercial lifecycle. Capabilities deployed for clinical diagnostics clients include Surveys/Trackers/ATUs to track dynamic precision medicine markets, Competitive Analysis to find the signal in the noise, and Market Landscaping and Sizing to understand size, growth, segmentation, and competitive dynamics.

Discover how data-driven solutions have helped stakeholders in Precision Medicine drive growth and stay ahead of the curve. From PE-backed life sciences tools platform development to investment diligence into leading oncology diagnostic providers and high-level commercial due diligence in digital pathology, the full range of investor needs in precision medicine is addressed. Capabilities deployed for financial services clients include Market Landscaping and Sizing, Pricing Strategy, and Target Identification — helping private equity firms and venture funds filter signal from noise, identify the best investment targets, and project revenues and competitive positioning of life sciences assets.

Discover how data-driven solutions have helped stakeholders in Precision Medicine drive growth and stay ahead of the curve. Engagements span global companion diagnostic guideline mapping and strategy, synthetic mRNA production landscape assessments, and internal lab buildout strategies for large pharmaceutical companies entering precision oncology. Capabilities deployed for pharma and biotech clients include Surveys/Trackers/ATUs to track rapidly shifting precision medicine markets, Pricing Strategy to triangulate optimal price points, and Market Landscaping and Sizing to understand the qualitative and quantitative dimensions of a given therapeutic or diagnostic opportunity.

Discover how data-driven solutions have helped stakeholders in Precision Medicine drive growth and stay ahead of the curve. Work spans VOC research and competitive assessments for novel multi-omic technologies, RWD biobank offering go-to-market strategies, and synthetic oligonucleotides market sizing for leaders in the space. Capabilities deployed for research tools clients include Voice-of-Customer Research — unbiased and unfiltered insights from real-world life science stakeholders — alongside Revenue Projection and Go-to-Market Strategy to support commercialization decisions and market entry for novel life science instruments, reagents, and platforms.

DeciBio designs and facilitates advisory board sessions, recruiting the right stakeholders and asking the right questions to maximize insight for life science clients. The offering includes full-service advisory board campaign management from participant identification and recruitment through questionnaire design, interview facilitation, and insights synthesis. AdBoard Campaign products span specific precision medicine topics including Pharma CDx Development and Commercialization (25 interviews), Biopharma Use of AI in Drug Discovery and Development, and other advisory-driven market intelligence initiatives. DeciBio serves as both a research capability and packaged product solution, enabling clients to tap specialized stakeholder expertise on emerging precision medicine topics.

DeciBio advises clients on biomarker strategy, companion diagnostic (CDx) partnerships, IVD launches, and how assays fit into clinical care pathways. The capability covers biomarker discovery strategy, diagnostic assay development planning, clinical validation pathways, regulatory strategy, and commercial positioning to ensure diagnostics achieve clinical adoption and market success. Case studies include Global Companion Diagnostic Guideline Mapping and Strategy for a large pharma company entering precision oncology and RNA-based Oncology Biomarker Market Landscape for cancer diagnostics companies, demonstrating comprehensive support across biomarker selection, CDx partnership strategy, assay design alignment, and clinical integration planning.

DeciBio identifies competitive signals and translates market data into strategic intelligence, helping clients understand competitor positioning and market dynamics in precision medicine. The capability combines primary research with landscape analysis to identify competitor strategies, product positioning, market entry patterns, and competitive vulnerabilities. Case study evidence includes Synthetic mRNA Production Landscape Assessment for a UK life science provider and VOC research with competitive assessment for a novel multi-omic technology company, demonstrating delivery of actionable competitive intelligence that informs go-to-market and product strategy decisions.

DeciBio identifies how a product best meets customer needs, which segments it resonates with most, and what drives decision-making across precision medicine customer groups. The capability combines market research and customer insights to define distinct customer segments, understand their unique needs and motivations, and identify the most attractive segments for product positioning and commercial execution. Positioned as a standalone Strategy Consulting capability on the services page, this capability supports product development, go-to-market strategy refinement, and commercial planning across precision medicine markets.

Bespoke data services that leverage proprietary and public data to extract actionable insights on customers and markets for precision medicine clients. DeciBio combines proprietary diagnostic usage data, market databases, and public sources to deliver custom analytics supporting market sizing, competitive benchmarking, customer segmentation, and trend analysis. Listed as a core capability on the services page and homepage with supporting data platforms portfolio, this offering enables clients to access ground-truth market data and generate evidence-based strategic insights across precision medicine segments.

DeciBio delivers deep-dive due diligence covering technology, market, customers, competitors, business model, regulatory strategy, and reimbursement for life science investment targets. The capability provides comprehensive assessment of target viability across commercial, competitive, regulatory, and market dimensions to support investment decision-making and post-acquisition integration planning. Listed as a standalone Strategy Consulting capability serving financial services clients alongside Target Identification, this offering delivers market-based, customer-validated due diligence that goes beyond financial assessment to evaluate technology differentiation, market adoption potential, competitive positioning, and reimbursement sustainability.

DeciBio builds actionable go-to-market strategies for precision medicine products, covering customer targeting, channel selection, competitive positioning, and commercial execution. The capability synthesizes market research, customer needs analysis, and competitive intelligence to define comprehensive commercial strategies that maximize market penetration and adoption. Case studies include Global Companion Diagnostic Guideline Mapping and Strategy for a large pharma company entering precision oncology and RWD Biobank Offering Go-to-Market Strategy for a top-20 U.S. health system, demonstrating delivery of market-tested go-to-market plans that address customer targeting, pricing, and channel strategy.

DeciBio identifies and connects clients with the most influential thought leaders in their specific precision medicine domain to shape strategy and market access. The capability uses proprietary databases and research to map key opinion leaders across therapeutic areas and diagnostic specialties, assess their influence and reach, and facilitate strategic engagements. Listed in navigation and services page as a standalone Market Research capability, supporting clients' market access, clinical validation, and commercial strategy development through informed KOL partnerships.

Rigorous qualitative and quantitative assessments of market size, growth, segmentation, and competitive dynamics for precision medicine sectors. DeciBio delivers comprehensive market intelligence covering competitor positioning, market dynamics, and detailed segmentation analysis to help life science companies understand their addressable market and strategic opportunities. Evidence from case studies includes Synthetic Oligonucleotides Market Sizing for oligonucleotide manufacturers and RNA-based Oncology Biomarker Market Landscape for cancer diagnostics companies, demonstrating delivery of detailed market assessments that inform product development and commercial strategy decisions.

DeciBio helps clients blazing trails with first-in-class technologies navigate commercialization strategy and create new market categories in precision medicine. The capability addresses the unique challenges of emerging technologies by combining market research, customer needs analysis, competitive intelligence, and commercial planning to develop strategies that educate markets, drive adoption, and establish new clinical standards. Case study evidence includes VOC research and competitive assessment for a novel multi-omic technology company facing a go/no-go development decision, demonstrating capability to guide clients through market category creation, customer education, and early adoption strategies for breakthrough precision medicine technologies.

DeciBio maps how patients and clinicians move through diagnostic and treatment pathways, helping clients understand where their products fit and what barriers they face. The capability combines qualitative research with pathway analysis to identify decision points, stakeholder roles, clinical workflows, and adoption barriers across the patient journey from initial presentation through diagnosis, treatment, and follow-up. Listed as a standalone capability with a dedicated service page, the offering provides actionable insights on clinical pathway integration, product positioning within workflows, and strategic opportunities to address unmet needs in diagnostic and treatment selection.

DeciBio uses a multi-pronged approach to triangulate optimal price points for precision medicine products and services, balancing adoption and market value. The capability integrates customer willingness-to-pay analysis, competitive pricing benchmarking, and reimbursement landscape assessment to recommend pricing strategies that maximize revenue while ensuring customer adoption. Case study evidence includes Pricing Strategy components within VOC research and competitive assessment for a novel multi-omic technology company and RWD Biobank Offering Go-to-Market Strategy, demonstrating capability to develop evidence-based pricing recommendations grounded in customer and market dynamics.

DeciBio uses qualitative and quantitative tools to ensure clients develop products that are optimally specified for target customers and competitive in future market conditions. The capability combines customer needs research, competitive benchmarking, and clinical/technical requirements analysis to guide product development roadmaps and feature prioritization. Positioned as a standalone Strategy Consulting capability and referenced in the RNA-based Oncology Biomarker Market Landscape case study, demonstrating capability to translate market insights into specific product requirements and specifications.

DeciBio builds data-driven revenue scenarios considering customer demand, product profile, competitive dynamics, regulation, and market factors for precision medicine products. The capability synthesizes market sizing research, customer adoption analysis, and competitive landscape assessment to develop realistic revenue projections and scenario models. Listed as a standalone Strategy Consulting capability on the services page, this offering supports investment decision-making, business planning, and commercial strategy development for life science companies and investors.

DeciBio designs and executes market tracking surveys and ATU (awareness, trial, usage) studies to monitor precision medicine market dynamics over time. The capability includes both custom tracking studies for individual clients and syndicated research products that monitor evolving stakeholder perceptions, adoption patterns, and competitive dynamics. Syndicated data products include the U.S. Oncology Genomics Tracker and Europe Oncology Genomics Tracker, which provide ongoing market intelligence on diagnostic adoption, workflow integration, and competitive positioning in oncology genomics markets.

DeciBio identifies the best investment or partnership targets at the intersection of technology, market, team, and timing for life science companies and investors. The capability combines market research, competitive analysis, and technology assessment to identify targets with strong market positioning, differentiated capabilities, and growth potential. Listed as a standalone Strategy Consulting capability and serving Financial Services clients making investment decisions in precision medicine, this offering provides market-informed target screening, prioritization, and opportunity assessment to support M&A and venture capital investment decisions.

DeciBio helps clients discover where their technology creates the most value, focusing commercialization efforts on the highest-impact applications in the life science market. The capability combines technology assessment with market research to identify the most promising clinical and commercial applications, prioritize development roadmaps, and guide go-to-market strategy toward highest-impact segments. Listed as a standalone Strategy Consulting capability on the services page, this offering supports technology platforms seeking to optimize commercialization priorities and identify the applications with strongest clinical and market potential.

Comprehensive, unbiased VOC research with real-world life science stakeholders to surface the motivations and decision-making of current and potential customers. DeciBio conducts deep stakeholder interviews and research with clinicians, laboratory directors, pharmacists, and end-users to understand customer needs, pain points, and purchasing drivers across precision medicine markets. Case studies include VOC research for a novel multi-omic technology company (~$100M company) and RWD Biobank Offering Go-to-Market Strategy for a top-20 U.S. health system, demonstrating the capability to translate customer insights into actionable competitive and strategic assessments.

A suite of proprietary databases offering lab-level ground-truth data on diagnostic testing practices, including the ID DxBook (infectious disease, 31 analytes), NGS Oncology DxBook, Digital Pathology DxBook, and Legacy DxBook — available for demo and licensing. DxBooks capture real-world diagnostic testing volumes, adoption patterns, and competitive positioning across precision medicine segments, providing clients with authoritative market intelligence for strategic planning, competitive benchmarking, and market sizing.

A quarterly subscription data product characterizing the current clinical use of genomic testing across U.S. oncology practices. The tracker monitors oncologist testing behaviors across clinical applications including genomic profiling, MRD/recurrence monitoring, and treatment response monitoring — capturing oncologist perspectives on test providers, adoption drivers, pain points, and expected future utilization. Each subscription includes 4 waves of data collected quarterly, enabling clients to track market shifts over time. Designed for strategy, commercial, and business development teams at NGS companies, diagnostics manufacturers, and biopharma organizations operating in the precision oncology space.

An AI-powered expert matching platform connecting life science organizations with curated experts from broad and niche precision medicine communities. Dexter uses smart matching capabilities to quickly identify the most relevant KOLs, clinicians, laboratory directors, and industry executives for advisory boards, interviews, and market research projects — with quick project turnaround times and coverage across diverse therapeutic areas, diagnostic specialties, and precision medicine domains. Designed for biopharma, diagnostics, and life science tools companies needing rapid access to validated expert perspectives.

A dynamic pipeline tracker providing up-to-date intelligence on assets in development across cell therapies, viral gene therapies, nucleic acid-based therapies, and antibody-drug conjugates. TheraTrack enables life science companies, investors, and biopharma organizations to monitor the evolving precision medicine pipeline landscape — tracking competitive assets, development stage progressions, and emerging therapeutic modalities in real time. Designed for strategy, business development, and competitive intelligence teams operating in advanced therapy and precision medicine markets.